[2025 Round-up] New diagnostic and therapeutic advancements for dementia in 2025

2025 has been a year marked by substantial advances in biomarkers and pharmacological treatments for Alzheimer's disease. Guidelines published in 2025 recommend the use of blood-based biomarkers for individuals who are cognitively impaired as part of a comprehensive diagnostic workup for suspected Alzheimer's disease.1 Real-world data from a behavioural neurology clinic showed that blood-based Alzheimer's disease biomarkers are not only diagnostically informative but also clinically actionable. These biomarkers are frequently ordered in diagnostically complex cases, can influence medication decisions, and help determine the need for additional confirmatory testing.